EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Benzinga11-19

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects. Topline data is expected in the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584789946?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-11-19 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584789946","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants","media":"Benzinga","content":"<div>\n<p>Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects.\nTopline data is expected in the...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-19 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects.\nTopline data is expected in the...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","article_id":"2584789946","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584789946","pubTimestamp":1763555400,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALZN":"Alzamend Neuro, Inc","BK4539":"次新股"},"translate_title":"独家：Alzamend在健康参与者中完成AL001研究的临床阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":1},"content_text":"Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects.\nTopline data is expected in the first quarter of 2026. Earlier, the company expected topline results from the first trial by year-end 2025, with follow-up trials in bipolar disorder, major depressive disorder, post-traumatic stress disorder, and Alzheimer's launching through early 2026.\nAlso Read: EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Its Phase 2 Trial Of Lead Program\nIn collaboration with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating the distinctive characteristics of AL001.\nAlzamend Neuro AL001 (LiProSal) is a novel, patented oral therapeutic drug candidate for the treatment of Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). It is designed as a safer and more effective lithium-delivery system compared to traditional lithium salts.\nThe primary objective is to assess how AL001 delivers lithium to the brain compared to marketed lithium salts, evaluating its ability to achieve better therapeutic efficacy while minimizing systemic side effects.\nThe clinical study utilized an engineered head coil developed by Tesla Dynamic Coils BV, which grants the capability for high-resolution, whole-brain lithium imaging, which allows for the precise quantification of lithium within specific brain structures.\nThe resulting proprietary imaging data sets will be used to establish a foundational reference, helping Alzamend accurately identify the optimal, disease-specific target doses of AL001.\nBy potentially removing the requirement for lithium therapeutic drug monitoring, AL001 could transform treatment for at-risk patient groups and enhance clinical outcomes.\nLithium is widely recognized as a highly effective first-line option for managing manic episodes and maintenance in BD, yet TDM challenges have limited its adoption.\nLithium salts approved by the U.S. Food and Drug Administration currently face a narrow therapeutic index, necessitating frequent clinician-monitored plasma lithium and blood chemistry tests to prevent adverse effects.\nThrough reduced systemic exposure, Alzamend's AL001 formulation may represent a paradigm shift in treating disorders such as Alzheimer's, by lowering the risks of kidney and thyroid complications commonly associated with conventional lithium regimens.\nThe company's secondary therapeutic drug candidate, ALZN002, is a proprietary \"active\" immunotherapy product, which means it is produced by the patient's immune system.\nALZN002 uses autologous dendritic cells engineered to target amyloid-beta proteins, aiming for safe, long-lasting reduction of beta-amyloid plaques—unlike antibody-based approaches that rely on foreign products.\nIn April 2023, Alzamend Neuro initiated a Phase 1/2A trial for ALZN002 to evaluate its safety, tolerability, and efficacy in 20-30 patients with mild to moderate Alzheimer's, comparing multiple ascending doses to a placebo.\nALZN Price Action: Alzamend Neuro shares were up 7.79% at $2.63 during premarket trading on Tuesday, according to Benzinga Pro data.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584789946","isCrawlerRequest":true}